Pemirolast potassium
Code | Size | Price |
---|
TAR-T1425-5mg | 5mg | £95.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1425-10mg | 10mg | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1425-25mg | 25mg | £125.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1425-50mg | 50mg | £139.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1425-100mg | 100mg | £172.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1425-200mg | 200mg | £201.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Pemirolast Potassium is the potassium salt form of pemirolast, a pyrimidinone derivative with antiallergic property. Pemirolast potassium exerts its action by blocking the antigen-mediated calcium ion influx into mast cells.
CAS:
100299-08-9
Formula:
C10H7KN6O
Molecular Weight:
266.305
Pathway:
GPCR/G Protein; Neuroscience; Immunology/Inflammation
Purity:
0.9989
SMILES:
[K+].Cc1cccn2c1ncc(-c1nnn[n-]1)c2=O
Target:
Histamine Receptor
References
1. Kemp JP, et al. Ann Allergy, 1992, 68(6), 488-491.
2. Tatsushima Y, et al. Eur J Pharmacol, 2011, 661(1-3), 57-62.
3. Itoh Y, et al. Neuropharmacology, 2004, 46(6), 888-894.
4. Abelson MB, et al. J Ocul Pharmacol Ther, 2002, 18(5), 475-488.